Hot Investor Mandate: Investing Holding Company Backed by Leading European Institutions Seeks Europe and US-Based Companies in All Life Science Sectors 

22 Jul

An investment holding company founded by leading European institutions has raised over €100 million from a base of more than 200 institutional and private shareholders. The firm invests from Seed to Series B stages, with a strong preference for early-stage companies and potential for follow-on funding. Check sizes can reach up to $2 million per company, with flexibility based on the stage of development. The firm is open to both leading and co-investing, and while it is primarily Europe-focused, it is increasingly pursuing U.S. opportunities. 

The firm invests across biotech, MedTech (including therapeutics, medical devices, and diagnostics), and digital health. It remains modality- and indication-agnostic, seeking opportunities with strong growth potential and technological innovation. 

There are no specific requirements for company founding teams, and the firm works closely with its portfolio companies to support their development. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Global Manufacturing Company Seeks Strategic Partnerships With Early-Stage Medical Device and Digital Health Companies Across the Globe  

22 Jul

A global manufacturing company, with over a century of history, is a leader in advanced materials and pressure-sensitive adhesive technologies. With a strong presence in the U.S. for many decades, it has built a reputation for innovation across industries including aerospace, electronics, healthcare, automotive, housing/construction, environmental applications, and general industry. 

In healthcare, the firm is actively seeking strategic partnerships with early-stage companies that complement its product lines. While it is open to meeting startups at the Series A stage, its focus is more on the development stage of technologies rather than funding rounds. The company has a global outlook and welcomes partnerships worldwide. 
 
The company is particularly interested in medical devices and digital health solutions. Priority technologies include sensors for applications such as injury prevention, rehabilitation for musculoskeletal disorders, stroke recovery, and neurological conditions. The company favors startups with prototypes and looks for technologies aligned with its existing products, such as flexible or stress sensors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: US-Based VC Invests in Tech-Bio Companies Achieving Breakthroughs in Drug Development, Precision Medicine, and More Across All Indications

22 Jul

A venture capital firm headquartered in the U.S. invests in pre-seed, seed, and opportunistic Series A tech-bio startups across the country. With access to a strong healthcare and life sciences network, the firm connects portfolio companies with strategic partners and resources to accelerate growth. Initial checks typically range from $300K to $1M, often through syndication or co-investment. 

The firm focuses on technology-driven biotechnology companies, particularly those leveraging AI, computational biology, and machine learning to achieve breakthroughs in drug development, diagnostics, precision medicine, and other healthcare innovations. It is indication-agnostic and prioritizes startups where technology forms the core of the value proposition and enables scalable impact. 

The firm does not enforce rigid requirements on company structure or team experience, instead seeking strong technical foundations, visionary leadership, and a clear path to commercialization. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Early-Stage VC Invests in Transformative Technologies Across the Globe that Address Mental Health Challenges

22 Jul

A venture capital firm invests in transformative mental health deep tech, including psychedelics and neurotechnology. The firm invests in Pre-Seed, Seed, and Series A companies, aiming to bridge the Series A funding gap and democratize access to frontier modalities at scale. Typical initial investments range from $250,000 to $2 million, with the possibility of follow-on funding. The firm is open to both leading and co-investing in deals, and may take board seats or observer roles on a case-by-case basis. It maintains a global investment scope and is not limited to opportunities within the U.S. 

The firm focuses on transformative technologies that address mental health challenges. Areas of particular interest include psychedelic medicines, especially non-hallucinogenic neuroplastogens (notably NCEs), and short-duration psychedelic compounds aligned with the Spravato medical model. It also invests in digital therapeutics and neurotechnology designed for mental health applications. While the firm is open to early-phase companies, it has a preference for those with strong IP and patent portfolios. It looks for innovations that can make a significant impact on mental health treatments and patient outcomes and places a strong emphasis on ethical conduct. 

The firm does not have strict requirements for founding teams. Its management team, composed of startup founders and operators, provides extensive support to portfolio companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

200% Pharma Tariff Threat: Impacts on Biotech Venture Investment

22 Jul

By Sougato Das, President and COO, LSN

Sougato-Das

The newly proposed 200% pharma tariff threat (not a reality yet, but Trump has indicated they will go into effect on August 1) hasn’t delivered an immediate market shock; biopharma stocks have remained steady, albeit flat. The 12-18 month grace period included in the tariff proposal gives large pharma wiggle room to pivot to US manufacturing while stockpiling to ride out the remaining 2 – 3 years required to make the transition. Predictably, there are concerns that such tariffs could increase drug costs, lead to shortages, impact profit margins (dampening appetite for investment/BD) and disrupt the supply chain.

The tariff threat has, however, catalyzed a strategic pivot toward U.S. manufacturing, with major firms like Biogen, J&J, Eli Lilly, Roche, Sanofi, and Merck spending billions in U.S. facilities.

In the biotech investment and BD community, the question is: how will/has this affect/ed investment and BD activity?

  • Overall biotech investment may slow as cost inflation pressures biotech valuations and investment capital.
  • It has been theorized that the pharma tariff threat has contributed to the IPO dry-up in life sciences (nearly all biotech IPOs since 2023 are trading below their IPO price). A continued drought would obviously have a negative impact on biotech venture investment.
  • If large pharma funnels billions into new manufacturing plants, that money must come from somewhere (usually R&D), and may signal a further slowdown in pharma partnering and investment.
  • An unpredictable economic environment could deter biotech investment. Such investor caution could lead to more selective funding rounds and a decrease in overall venture capital flowing into the sector.
  • Finally, it’s well-understood that investors are becoming more selective, focusing on companies with de-risked assets, strong scientific data, and clear commercialization potential.

On the positive side, we see pharma biotech acquisitions up, simply due to how inexpensive small biotechs are to buy right now.

These factors make it far more critical this year than in 2024 or 2023, that you meet with elevated numbers of investment or strategic partners to overcome the above hurdles. Partnering events like RESI are the best way to have 10-20 investor meetings in a day. Using Life Science Nation’s BD Assist, where we set up investor meetings for you, is another option to supercharge your fundraise.

Tags: , , , , , ,

London Life Sciences Partnering & Venture Investment Week 

22 Jul

By Greg Mannix, VP, EMEA Business Development, LSN

The first week of December marks the largest life science partnering and venture week in the UK. If you’re raising pre-seed, seed, round A or round B, or are in phase 2 or earlier development, Life Science Nation’s (LSN) RESI London, One Nucleus’ Gensis, and ELRIG/SLAS events offer far better partnering, investment, learning, and procurement opportunities compared to the health care week in late November (concurrent with the Jefferies investment banking event), for a fraction of the cost. That week tends to focus on recent IPOs and companies that are close to IPO, along with phase 3 or more advanced companies looking for partnerships. If you’re not at that stage, save your critical conference and travel budgets for an event series that’s right for you.

RESI London and Gensis are combining to offer a multi-day investment, partnering and thought leadership event for venture stage companies seeking funding and strategic alliances:

December 2nd

  • Free course on fundraising, including networking, offered by LSN
  • Free ELRIG / SLAS drug-discovery focused networking event
  • Genesis welcome reception for Genesis and RESI registrants

December 3rd

  • Genesis “Maximising Returns from Life Science Innovation” KOL & partnering event
  • Genesis evening reception

December 4th

  • RESI London fundraising & partnering event, featuring 200 investors & in-licensors
  • RESI London evening reception

During the entire week you are also welcome to attend the Genesis Fringe events for free including networking breakfasts, lunches and other events with topics similar to Building a World Class Life Science Ecosystem, Accessing US Investors and Exits, IP Strategies in Advanced Therapy Dealmaking, Top Talent Trends for Life Sciences in 2025 and Pay Transparency, R&D to Commercialization in Rare Diseases, and more.

Join us in the rich life science ecosystem in London during the first week of December. To learn more, contact us at RESI@lifesciencenation.com

Register for RESI London

Tags: , , , ,

MantaBio: RESI Boston Pitch Challenge Winner Shares What’s Next 

22 Jul

By Caitlin Dolegowski, Marketing Manager, LSN

CaitiMantaBio earned third place in the Innovator’s Pitch Challenge (IPC) at RESI Boston this past June, standing out among a competitive field of early-stage life science companies. In this interview, Co-Founder and President Carter Boisfontaine shares insights into the company’s fundraising efforts, their experience at RESI, and what’s ahead for the team.

Watch the interview:

Interested in pitching your company at RESI?

Applications are now open for the Innovator’s Pitch Challenge at RESI Boston, September 17, 2025. Selected companies receive full access to the conference, partnering meetings with investors, and exhibit space in the RESI Exhibition Hall. New! The September 2025 IPC Pitch Package now includes an optional second RESI pass at no additional cost, allowing an additional team member to attend and participate in partnering. Apply now!

Apply to Pitch at RESI Boston Sept. 2025

Tags: , , , , , , , ,

← Older Entries
Newer Entries →